H1N1 Swine Flu Vaccine Makes German Man Extremely Sick During Clinical Trials

Fight Back H1N1
Sep. 23, 2009

Berlin : Last week Australian H1N1 Swine Flu Vaccine Panvax Manufacturer “Listed Guillian-Barre Syndrome as vaccine side effect”. And now a German man who participated in H1N1 Swine Flu Vaccine clinical trials has said that he became seriously ill as a consequence of theH1N1 Swine Flu Vaccine, according to reports in the German mainstream media. Axel Sch., a 40 year old man with a degree in business, enrolled for the “swine flu” clinical trials at Munich’s Ludwig-Maximilians-University led by Dr Frank von Sonnenburg.

After receiving an injection on August 10th he became seriously ill.

“The injection made me sick – the test is irresponsible,” he said.

He felt the impact just a few hours after the injection, he said.

“I felt totally shattered. On the third day, I felt pain in my kidneys and head and I got a fever. Then I had a coughing fit – and my washbasin was suddenly red. It was blood.”

Sonnenburg has denied the patient’s claims, but good clinical practice requires a doctor to include all the side effects, no matter how serious to avoid falsifying data.

The failure of Sonnenburg to acknowledge the report of Axel Sch. raises serious questions about just how independent and valid the clinical study results on this new and untested vaccine material with adjuvant can be considered.

It appears that the vaccine material being tested on Axel Sch. was from GSK which has produced a swine flu vaccine using the oil-based adjuvant containing squalene.

GSK issued a press release on Monday 14th September maintaining that a one dose “swine flu” vaccine with adjuvants had proved successful in its first clinical trials in Germany. Source .

In other development German anti corruption watchdog criticises key government vaccine body for links to big pharma. And a Germans Sue Own Government Over H1N1 Flu Quarantine .

Health Secretary Klaus Theo Schroeder said after a meeting of health ministers of the seven leading industrialized nations (G-7) and Mexico in Brussels, the government could hold on to Impfstart mid-October.